DAX-0,02 % EUR/USD+0,06 % Gold+0,37 % Öl (Brent)-0,25 %

AVEO Pharmaceuticals



Begriffe und/oder Benutzer

 

AVEO Pharmaceuticals Inc

"AVEO Oncology is committed to discovering, developing and commercializing targeted therapies to treat patients with cancer. AVEO’s proprietary Human Response PlatformTM provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. AVEO’s product candidates include AV-203, ficlatuzumab, tivozanib and AV-380."

Produktkandidaten

AV-203
"successfully completed a Phase 1 safety study"

Ficlatuzumab
"An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints"

Tivozanib
"On February 14, 2014, AVEO and Astellas announced their decision to terminate their collaboration for the development and commercialization of tivozanib. Costs for on-going tivozanib-related expenses will be shared by the parties. Based on the terms of the agreement, all rights for tivozanib will revert to AVEO in August 2014, six months after Astellas notified AVEO of its intention to terminate the agreement. AVEO plans to explore potential partnership opportunities for the further clinical development of tivozanib."

AV-380 (GDF-15 Program)
"The clinical program will be designed to obtain rapid proof of clinical activity with first-in-human clinical trials planned for the second half of 2015."


Umsätze nehmen deutlich zu:
Historical Prices
Date Open High Low Close Volume Adj
Close
2014/06/10 1.12 1.27 1.10 1.24 2,568,201 1.24
2014/06/09 1.02 1.14 1.01 1.10 1,345,182 1.10
2014/06/06 1.03 1.03 1.01 1.02 329,959 1.02
2014/06/05 1.02 1.05 1.01 1.01 752,003 1.01
2014/06/04 1.03 1.04 1.00 1.02 412,030 1.02
2014/06/03 1.06 1.08 1.00 1.04 1,138,222 1.04
2014/06/02 1.17 1.19 1.06 1.09 1,075,564 1.09
2014/05/30 1.14 1.17 1.09 1.11 684,167 1.11
2014/05/29 1.07 1.14 1.06 1.12 806,826 1.12
2014/05/28 1.09 1.09 1.00 1.08 1,223,743 1.08
2014/05/27 1.10 1.13 1.04 1.07 1,219,628 1.07
2014/05/23 1.08 1.10 1.05 1.07 449,550 1.07
2014/05/22 1.11 1.13 1.06 1.07 735,378 1.07
2014/05/21 1.12 1.14 1.06 1.11 381,417 1.11
2014/05/20 1.17 1.17 1.10 1.11 491,967 1.11
2014/05/19 1.13 1.18 1.12 1.16 444,059 1.16
2014/05/16 1.12 1.18 1.11 1.13 736,276 1.13
2014/05/15 1.17 1.19 1.09 1.11 611,708 1.11
2014/05/14 1.19 1.22 1.14 1.16 715,125 1.16
2014/05/13 1.22 1.27 1.16 1.19 579,736 1.19
2014/05/12 1.20 1.25 1.16 1.20 567,771 1.20
2014/05/09 1.08 1.18 1.06 1.18 518,734 1.18
2014/05/08 1.15 1.24 1.09 1.10 654,635 1.10
2014/05/07 1.17 1.25 1.14 1.15 774,478 1.15


Quartalsbericht

Auf IHUB http://ih.advfn.com/p.php?pid=financials&btn=istart_date&ctl…

Auf Aveo Webseite http://services.corporate-ir.net/SEC/Document.Service?id=P3V…



Nachträglich noch Nasdaq Chart (ich habe wohl eben auf die falsche Börse geklickt).

AVEO Pharmaceuticals, Inc. (AVEO) in Focus: Stock Rises 7.8% - Tale of the Tape

Read more: http://www.nasdaq.com/article/aveo-pharmaceuticals-inc-aveo-in-focus-stock-rises-78-tale-of-the-tape-cm360275#ixzz34KWKsDY5
Market Capitalisation 65.3 mil
Latest Shares Outstanding 52.3 mil
Antwort auf Beitrag Nr.: 47.136.592 von Dr_Depotleiche am 11.06.14 14:02:25Danke für Info. Bin gespannt auf ACHN. Habe gestern die Hälfte mit fettem Plus verkauft. Der Rest vielleicht heute, warte 15:30 Uhr...mal schauen was sie drüben veranstalten...
 Durchsuchen


Beitrag zu dieser Diskussion schreiben